ALTEOGEN Inc - Asset Resilience Ratio

Latest as of June 2026: 49.53%

ALTEOGEN Inc (196170) has an Asset Resilience Ratio of 49.53% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of ALTEOGEN Inc to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩366.47 Billion
≈ $248.35 Million USD Cash + Short-term Investments

Total Assets

₩739.91 Billion
≈ $501.43 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how ALTEOGEN Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of ALTEOGEN Inc.

Liquid Assets Composition Over Time

This chart breaks down ALTEOGEN Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ALTEOGEN Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩366.47 Billion 49.53%
Total Liquid Assets ₩366.47 Billion 49.53%

Asset Resilience Insights

  • Very High Liquidity: ALTEOGEN Inc maintains exceptional liquid asset reserves at 49.53% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

ALTEOGEN Inc Industry Peers by Asset Resilience Ratio

Compare ALTEOGEN Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Biotechnology 33.23%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 65.12%

Annual Asset Resilience Ratio for ALTEOGEN Inc (2014–2025)

The table below shows the annual Asset Resilience Ratio data for ALTEOGEN Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 52.04% ₩363.64 Billion
≈ $246.43 Million
₩698.74 Billion
≈ $473.53 Million
+6.75pp
2024-12-31 45.29% ₩185.25 Billion
≈ $125.54 Million
₩409.01 Billion
≈ $277.18 Million
+2.10pp
2023-12-31 43.19% ₩110.61 Billion
≈ $74.96 Million
₩256.10 Billion
≈ $173.56 Million
-8.76pp
2022-12-31 51.95% ₩127.54 Billion
≈ $86.43 Million
₩245.49 Billion
≈ $166.37 Million
-25.64pp
2021-12-31 77.59% ₩202.00 Billion
≈ $136.90 Million
₩260.34 Billion
≈ $176.43 Million
-6.36pp
2020-12-31 83.95% ₩133.66 Billion
≈ $90.58 Million
₩159.21 Billion
≈ $107.89 Million
+11.87pp
2019-12-31 72.08% ₩61.98 Billion
≈ $42.00 Million
₩85.98 Billion
≈ $58.27 Million
-0.09pp
2018-12-31 72.17% ₩51.52 Billion
≈ $34.91 Million
₩71.38 Billion
≈ $48.37 Million
-3.23pp
2017-12-31 75.40% ₩32.43 Billion
≈ $21.98 Million
₩43.01 Billion
≈ $29.15 Million
-2.43pp
2016-12-31 77.82% ₩37.32 Billion
≈ $25.29 Million
₩47.95 Billion
≈ $32.49 Million
+29.84pp
2015-12-31 47.99% ₩18.90 Billion
≈ $12.81 Million
₩39.39 Billion
≈ $26.69 Million
+9.39pp
2014-12-31 38.60% ₩14.65 Billion
≈ $9.93 Million
₩37.96 Billion
≈ $25.72 Million
--
pp = percentage points

About ALTEOGEN Inc

KQ:196170 Korea Biotechnology
Market Cap
$12.26 Billion
₩18.09 Trillion KRW
Market Cap Rank
#1898 Global
#40 in Korea
Share Price
₩260000.00
Change (1 day)
+0.00%
52-Week Range
₩260000.00 - ₩559000.00
All Time High
₩559000.00
About

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more